Published in Lancet on January 26, 1980
Immunocytochemical staining of estrogen receptor in paraffin sections of human breast cancer by use of monoclonal antibody: comparison with that in frozen sections. Proc Natl Acad Sci U S A (1985) 1.24
Histochemical detection of oestrogen receptors in breast carcinoma: a successful technique. Br J Cancer (1986) 1.13
Histochemical detection of oestrogen receptors: a progress report. Br J Cancer (1982) 0.95
Biochemical assessment of histochemical methods for oestrogen receptor localisation. J Clin Pathol (1982) 0.90
Histochemical studies of human breast cancer using a monoclonal antibody against an oestrogen receptor-related antigen. Br J Cancer (1987) 0.81
Correlations of the receptor content and ultrastructure of breast cancer cells. Arch Gynecol (1982) 0.76
Hormone receptors and human breast cancer. Br Med J (1980) 0.75
Pathology-epitomes of progress: steroid hormone receptors in histologic diagnosis. West J Med (1982) 0.75
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res (1997) 4.22
An in vitro method for assessing the plaque forming ability of oral bacteria. Arch Oral Biol (1967) 3.11
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet (2004) 3.10
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol (2006) 2.94
A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer (1984) 2.89
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer (2004) 2.87
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene (1987) 2.67
Familial breast cancer. BMJ (1994) 2.54
Uptake of screening and prevention in women at very high risk of breast cancer. Lancet (2001) 2.45
Blindness after treatment for malignant hypertension. Br Med J (1979) 2.39
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol (1997) 2.39
Perception of risk in women with a family history of breast cancer. Br J Cancer (1993) 2.32
The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology (1995) 2.27
Method for the isolation of highly purified Salmonella flagellins. J Clin Microbiol (1985) 2.27
Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet (2003) 2.24
Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet (1980) 2.19
The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene (1989) 2.02
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat (2001) 1.88
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat (1999) 1.84
Screening for psychiatric morbidity in patients with advanced breast cancer: validation of two self-report questionnaires. Br J Cancer (1991) 1.83
Non-standard management of breast cancer increases with age in the UK: a population based cohort of women > or =65 years. Br J Cancer (2007) 1.80
Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab (1997) 1.79
The impact of genetic counselling on risk perception in women with a family history of breast cancer. Br J Cancer (1994) 1.75
HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol (2011) 1.73
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer (2001) 1.70
Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet (1983) 1.69
Human cerebral hemispheres develop at different rates and ages. Science (1987) 1.68
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer (1996) 1.67
The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer (1989) 1.65
The localization of laminin mRNA and protein in the postimplantation embryo and placenta of the mouse: an in situ hybridization and immunocytochemical study. Development (1988) 1.64
The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) (2010) 1.61
Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol (1999) 1.61
Odontomyces viscosus, gen. nov., spec. nov., a filamentous microorganism isolated from periodontal plaque in hamsters. Sabouraudia (1965) 1.61
The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas. Int J Cancer (1984) 1.61
Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. J Natl Cancer Inst (1997) 1.58
Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells. J Urol (2007) 1.57
Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet (1984) 1.56
Effects of magnesium on the dynamic instability of individual microtubules. Biochemistry (1990) 1.54
Pathological and biological features of mammographically detected invasive breast carcinomas. Br J Cancer (1995) 1.54
Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia (1998) 1.52
A filamentous microorganism isolated from periodontal plaque in hamsters. 1. Isolation, morphology and general cultural characteristics. Sabouraudia (1963) 1.52
Identification of microtubule binding sites in the Ncd tail domain. Biochemistry (1999) 1.51
Tumour angiogenesis as a prognostic marker in infiltrating lobular carcinoma of the breast. J Pathol (1996) 1.49
Can hair be used to screen for breast cancer? J Med Genet (2000) 1.49
There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions. J Clin Pathol (2003) 1.46
A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther (2000) 1.45
Neuropathic joints. Semin Arthritis Rheum (1972) 1.44
Screening by mammography, women with a family history of breast cancer. Eur J Cancer (1998) 1.44
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol (1996) 1.44
Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am (2006) 1.43
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcaemia in two hospital populations. Clin Endocrinol (Oxf) (1994) 1.42
Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab (1999) 1.42
The relationship of body weight to response to endocrine therapy, steroid hormone receptors and survival of patients with advanced cancer of the breast. Br J Cancer (1988) 1.42
Parathyroid hormone related protein and hypercalcaemia in breast cancer. BMJ (1991) 1.41
Brain microtubule-associated proteins modulate microtubule dynamic instability in vitro. Real-time observations using video microscopy. J Cell Sci (1992) 1.41
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole. Eur J Cancer (2004) 1.39
Effect of clothing on dispersal of Staphylococcus aureus by males and females. Lancet (1974) 1.39
The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A (1989) 1.38
Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer (1993) 1.36
Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene (1991) 1.36
Dynamic instability of microtubules. Bioessays (1987) 1.36
Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet (1983) 1.35
A filamentous microorganism isolated from periodontal plaque in hamsters. II. Physiological and biochemical characteristics. Sabouraudia (1963) 1.34
Psychological support needs for women at high genetic risk of breast cancer: some preliminary indicators. Psychooncology (1999) 1.32
Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer (1992) 1.31
Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet (1986) 1.30
Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. J Med Genet (2001) 1.28
Cancer experience in the relatives of an unselected series of breast cancer patients. Br J Cancer (1994) 1.28
A metastable intermediate state of microtubule dynamic instability that differs significantly between plus and minus ends. J Cell Biol (1997) 1.27
Carcinomatous meningitis in solid tumours. Ann Oncol (1996) 1.27
A comparison of three assays used for the in vitro chemosensitivity testing of human tumours. Br J Cancer (1984) 1.25
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol (1990) 1.25
Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer (2006) 1.24
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet (2011) 1.23
Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ (1988) 1.23
A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol (1986) 1.22
Impact of a national external quality assessment scheme for breast pathology in the UK. J Clin Pathol (2006) 1.22
Psychiatric morbidity in patients with advanced cancer of the breast: prevalence measured by two self-rating questionnaires. Br J Cancer (1991) 1.21
Evaluation of nucleic acid-based test (PACE 2C) for simultaneous detection of Chlamydia trachomatis and Neisseria gonorrhoeae in endocervical specimens. J Clin Microbiol (1995) 1.21
Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. Int J Cancer (1991) 1.21
The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer (1988) 1.19
Helicopter cooling of heatstroke victims. Aviat Space Environ Med (1987) 1.19
Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer (2007) 1.19
Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer (2011) 1.19
Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet (2009) 1.18
Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancet (1984) 1.18
Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer (1991) 1.18
The effects of drugs that cause neutropenia upon colony formation by bone marrow cells in semi-solid agar. Clin Sci Mol Med (1974) 1.17
Expression of ykdA, encoding a Bacillus subtilis homologue of HtrA, is heat shock inducible and negatively autoregulated. J Bacteriol (2000) 1.17
Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer (1994) 1.16
Leucocyte migration inhibition with aggregated gamma globulin in patients with rheumatoid arthritis. Clin Exp Immunol (1973) 1.16
Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur J Cancer (1992) 1.16
Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. J Pathol (2003) 1.16
Changes in the extracellular matrix of the normal human breast during the menstrual cycle. Cell Tissue Res (1992) 1.14